Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,592,441 to Rosetta Genomics. The patent relates to human microRNA miR-193b, as well as to complementary probes and vectors. This is the third patent issued to Rosetta Genomics by the USPTO. [More]

US Spine® has announced that it has been awarded patent number 7,608,094, the second in a series of patents for facet fixation. This patent provides protection to the company for its method of facet fixation using the Facet Gun™ and Facet Bolt®. Additional patents covering other devices and methods are expected to follow. [More]

New Haven, Conn.-Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases. [More]

BioMarin Pharmaceutical Inc. announced today that the United States Patent and Trademark Office has issued a patent covering the approved administration of Kuvan® (sapropterin dihydrochloride) with food for the treatment of phenylketonuria (PKU). The patent expires in 2024. [More]

NovaDel Pharma Inc., today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. Patent Application No. 10/671,715, entitled “Buccal, Polar and Non-polar Spray Containing Zolpidem,” which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaMist™ Oral Spray spray technology. [More]

AdvanSource Biomaterials Corporation, a leading developer of advanced polymer materials for a broad range of medical devices, today announced the recent filing of a patent for its newly launched ChronoSil polymer product, a silicone-urethane copolymer. This patent application relates to silicone-urethane copolymers and methods for making ChronoSil. [More]

Imagenetix, Inc., announced today the issuance of a new U.S. patent (No. 7,612,111). The patent provides intellectual property protection for Imagenetix's 1-TDC early stage drug candidate for the prevention and treatment of periodontal disease. [More]

Peregrine Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,611,704, which includes broad claims covering anti-viral uses of phosphatidylserine (PS)-targeting antibodies including Peregrine's lead clinical compound, bavituximab. PS is a unique marker exposed on the surface of virally infected cells that can be targeted to treat a broad spectrum of virus infections. [More]

Foamix Ltd., a leading developer of topical foams for dermatological and gynecological use, announced today that it has been awarded Mexican Patent Registration No. 268451 entitled "Cosmetic and Pharmaceutical Foam." The patent covers Foamix's vehicles, compositions and cosmetic and pharmaceutical uses thereof based on the company's Emollient Foam technology platform. [More]

Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/833,323, which covers the use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate. Once issued, this patent will expire in February 2025. [More]

Entest BioMedical announced today it has filed a second patent application in the area of Chronic Obstructive Pulmonary Disease (COPD). This new patent application builds upon the Company’s previously filed COPD patent application and involves the use of photoceutical devices to target stem cells toward areas impacted by COPD in the lungs. [More]

NanoLogix, Inc. announces that the company has recently filed BNP™ (BioNanoPore) national patent applications in China, Japan, India, Brazil, Russia and the EU. These applications were filed in order to obtain intellectual property protection for the company's technology in countries viewed as representing the largest potential international market for BNP rapid detection, a revolutionary sandwiched-membrane Petri-based technology that can reduce microorganism detection times by 100-400%. [More]

IP Overview HIV Therapy 2009” ( www.frinnov.fr/en/ip-overview/sciences-de-la-vie/hiv-therapy-2.html ) establishes a panorama of the patents claiming “HIV and AIDS treatments” and analyses the key and emerging thematic and the strategic positions of the actors involved in this sector. In order to fully analyze this field, the information coming from 6800 published patents and patent applications was aggregated. [More]

Biomoda, Inc. (OTCBB: BMOD), an Albuquerque-based cancer diagnostics company, announces that it has received notice of allowance for a U.S. Patent protecting the proprietary formula for the composition that binds to cancer cells which is utilized in Biomoda’s screening assay for the early detection of cancer [More]

mPhase Technologies, Inc. reported today that it has been granted a United States patent for its concept for a battery that is safer for the environment. mPhase's "greener" battery technology could potentially help to reduce the harmful residual chemicals in a battery once it has reached the end of its life and is discarded. [More]